Phospho-DOK2 (Tyr142) Polyclonal Antibody | Invitrogen 44-264A product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Phospho-DOK2 (Tyr142) Polyclonal Antibody

catalog :

44-264A

quantity :

100µL

price :

US 330.00

clonality :

polyclonal

host :

rabbit

conjugate :

nonconjugated

antigen modification :

phosphorylated

reactivity :

mouse

application :

western blot

product information

Product Type :

Antibody

Product Name :

Phospho-DOK2 (Tyr142) Polyclonal Antibody

Catalog # :

44-264A

Quantity :

100µL

Price :

US 330.00

Clonality :

Polyclonal

Purity :

Antigen affinity chromatography

Host :

Rabbit

Reactivity :

Mouse

Applications :

Western Blot: Assay Dependent

Species :

Mouse

Isotype :

IgG

Storage :

-20°C

Description :

Docking proteins interact with receptor tyrosine kinases and mediate particular biological responses using signal transduction. Dok-2 acts as a multiple docking protein downstream of receptor or non-receptor tyrosine kinases. By this mechanism it acts to negatively regulate signal transduction and cell proliferation controlled by cytokines in a feedback loop. Dok-2 is highly expressed in cells and tissues of hematopoietic origin as well as in lung. Expression of bcr/abl induces additional tyrosine phosphorylation of the Dok1 and Dok2 proteins and their association with Ras-GAP. Thus, it is suspected that DOK association regulates GAP activity toward Ras and that the Dok proteins serve as mediators of bcr-abl signaling. The role of Dok proteins in bcr-abl regulation may also be implicated in chronic myelogenous leukemia (CML), which is characterized by a Philadelphia chromosome translocation t(9;22). Such a mutation would result in a p210-bcr/abl chimeric protein-tyrosine kinase which has been found in many CML cases.

Immunogen :

The antiserum was produced against a chemically synthesized phosphopeptide derived from a region of mouse Dok-2 that contains tyrosine 142 (tyrosine 139 in the human sequence).

Format :

Liquid

Applications w/Dilutions :

Western Blot: Assay Dependent

Aliases :

Docking protein 2, Downstream of tyrosine kinase 2, p56(dok-2), DOK2